Table 4 Outcome measures
From: Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol
Domain | Outcome measure |
|---|---|
Primary outcome measures | |
Behavioral domain | |
Anxiety | PROMIS Anxiety (v2.0) PROMIS Psychological stress experiences (v1.0) |
Mood problems | PROMIS Depressive symptoms (v2.0) PROMIS Life satisfaction (v1.0) |
Sleep problems | PROMIS Sleep-related impairment (v1.0) PROMIS Sleep disturbance (v1.0) |
Fatigue | PROMIS Fatigue (v2.0) |
Physical complaints | PROMIS Physical stress experiences (v1.0) |
Daily functioning and participation | PROMIS Cognitive function (v.1.1), VABS |
Problems in social interaction and communication | PROMIS Peer relationships (v2.0) |
Secondary outcome measures | |
Behavioral domain | |
Social communication and interaction | SRS-2 (subscales social awareness, social cognition, social communication, social motivation) |
Restricted, repetitive patterns of behavior | SRS-2 (subscale mannerisms) RBS-r |
Sensory stimulation tolerance | SP-NL |
Sensitivity to sensory stimuli | SP-NL |
Aberrant behavior | ABC |
Functional domain | |
Cognitive | Emma-toolbox |
Neurophysiological | rsEEG |
Translational domain | |
Genetic | Whole exome sequencing |
Cellular | Assays on iPSC-derived neuronal models |